These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

197 related items for PubMed ID: 12820306

  • 1. Trypsinogen activation peptide (TAP) expression in gallbladder bile identifies bilio-pancreatic carcinoma.
    Brockmann JG, Hernandez CA, Emparan C, Wolters H, Haier J, Dietl KH, Senninger NJ.
    Anticancer Res; 2003; 23(2A):819-25. PubMed ID: 12820306
    [Abstract] [Full Text] [Related]

  • 2. Gallbladder bile tumor marker quantification for detection of pancreato-biliary malignancies.
    Brockmann J, Emparan C, Hernandez CA, Sulkowski U, Dietl KH, Menzel J, Wolters H, Glodny B, Senninger N.
    Anticancer Res; 2000; 20(6D):4941-7. PubMed ID: 11326643
    [Abstract] [Full Text] [Related]

  • 3. The value of biliary amylase and Hepatocarcinoma-Intestine-Pancreas/Pancreatitis-associated Protein I (HIP/PAP-I) in diagnosing biliary malignancies.
    Chen CY, Lin XZ, Wu HC, Shiesh SC.
    Clin Biochem; 2005 Jun; 38(6):520-5. PubMed ID: 15885230
    [Abstract] [Full Text] [Related]

  • 4. A new strategy for the application of CA19-9 in the differentiation of pancreaticobiliary cancer: analysis using a receiver operating characteristic curve.
    Kim HJ, Kim MH, Myung SJ, Lim BC, Park ET, Yoo KS, Seo DW, Lee SK, Min YI.
    Am J Gastroenterol; 1999 Jul; 94(7):1941-6. PubMed ID: 10406263
    [Abstract] [Full Text] [Related]

  • 5. [Role of carcinoembryonic antigen, carbohydrate antigen 19-9 and cytology of bile in diagnosis of biliary and pancreatic cancer].
    Matsuda M, Shimizu Y, Chikamatsu E, Takayanagi K, Ishigure H, Murakami S, Odani K.
    Nihon Geka Gakkai Zasshi; 1991 Jun; 92(6):716-21. PubMed ID: 1886576
    [Abstract] [Full Text] [Related]

  • 6. [Computerized methods in the diagnosis and prognosis of surgically treated bilio-pancreatic diseases].
    Festa T, Foco A, Serenthà U, Enrichens F, Sciascia C, Caponi R, Manconi P, Grande L, Vogliolo B, Cardone M, Fornero G, Barberio V, Giordano A, Curti B, Pasquino M.
    Minerva Med; 1983 Feb 25; 74(7):289-300. PubMed ID: 6338420
    [Abstract] [Full Text] [Related]

  • 7. Usefulness of bile cytology in the diagnostic management of patients with biliary tract obstruction.
    Cobb CJ, Floyd WN.
    Acta Cytol; 1985 Feb 25; 29(2):93-100. PubMed ID: 2984868
    [Abstract] [Full Text] [Related]

  • 8. Ki-ras mutations in codon 12 and p53 mutations (biomarkers) and cytology in bile in patients with hepatobiliary-pancreatic carcinoma.
    Yamaguchi K, Nakano K, Nagai E, Chijiiwa K, Kinoshita M, Ohta M, Tanaka M.
    Hepatogastroenterology; 2005 Feb 25; 52(63):713-8. PubMed ID: 15966189
    [Abstract] [Full Text] [Related]

  • 9. Fibronectin in human bile fluid for diagnosis of malignant biliary diseases.
    Körner T, Kropf J, Hackler R, Brenzel A, Gressner AM.
    Hepatology; 1996 Mar 25; 23(3):423-8. PubMed ID: 8617420
    [Abstract] [Full Text] [Related]

  • 10. [Urine diacetylspermine as a novel tumor marker for pancreatobiliary carcinomas].
    Yamaguchi K, Nagano M, Torada N, Hamasaki N, Kawakita M, Tanaka M.
    Rinsho Byori; 2004 Apr 25; 52(4):336-9. PubMed ID: 15164602
    [Abstract] [Full Text] [Related]

  • 11. Mac-2-binding protein is a diagnostic marker for biliary tract carcinoma.
    Koopmann J, Thuluvath PJ, Zahurak ML, Kristiansen TZ, Pandey A, Schulick R, Argani P, Hidalgo M, Iacobelli S, Goggins M, Maitra A.
    Cancer; 2004 Oct 01; 101(7):1609-15. PubMed ID: 15378479
    [Abstract] [Full Text] [Related]

  • 12. [Fibronectin in human bile--a new parameter for diagnosis of malignant bile duct processes?--A pilot study].
    Körner T, Kropf J, Jaspersen D, Schorr W, Hammar CH, Gressner AM.
    Z Gastroenterol; 1994 Feb 01; 32(2):87-90. PubMed ID: 8165831
    [Abstract] [Full Text] [Related]

  • 13. [Peroral endoscopical diagnosis for the early stage of cancer in bilio-pancreatic system].
    Murashima Y, Suga T, Koito K, Miyakawa H, Sato T.
    Rinsho Byori; 1990 Mar 01; 38(3):231-9. PubMed ID: 2190021
    [Abstract] [Full Text] [Related]

  • 14. The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer.
    Ni XG, Bai XF, Mao YL, Shao YF, Wu JX, Shan Y, Wang CF, Wang J, Tian YT, Liu Q, Xu DK, Zhao P.
    Eur J Surg Oncol; 2005 Mar 01; 31(2):164-9. PubMed ID: 15698733
    [Abstract] [Full Text] [Related]

  • 15. [Tumor markers in the diagnosis of tumors in the subhepatic area].
    Dufek V, Petrtýl J, Klener P, Chmel J.
    Vnitr Lek; 1994 Jun 01; 40(6):350-3. PubMed ID: 8073643
    [Abstract] [Full Text] [Related]

  • 16. Comparison of tumor marker CA 242 with CA 19-9 and carcinoembryonic antigen (CEA) in pancreatic cancer.
    Ozkan H, Kaya M, Cengiz A.
    Hepatogastroenterology; 2003 Jun 01; 50(53):1669-74. PubMed ID: 14571813
    [Abstract] [Full Text] [Related]

  • 17. [Does cholestasis change the clinical usefulness of CA 19-9 in pacreatobiliary cancer?].
    Mery CM, Duarte-Rojo A, Paz-Pineda F, Gómez E, Robles-Díaz G.
    Rev Invest Clin; 2001 Jun 01; 53(6):511-7. PubMed ID: 11921523
    [Abstract] [Full Text] [Related]

  • 18. Activation of telomerase and its diagnostic application in biopsy specimens from biliary tract neoplasms.
    Niiyama H, Mizumoto K, Kusumoto M, Ogawa T, Suehara N, Shimura H, Tanaka M.
    Cancer; 1999 May 15; 85(10):2138-43. PubMed ID: 10326691
    [Abstract] [Full Text] [Related]

  • 19. DNA image cytometry in the differential diagnosis of benign and malignant lesions of the bile duct, the pancreatic duct and the papilla of Vater.
    Biesterfeld S, Deacu L.
    Anticancer Res; 2009 May 15; 29(5):1579-84. PubMed ID: 19443369
    [Abstract] [Full Text] [Related]

  • 20. [The clinical value of tumor marker CA50 and CA242 in digestive tract cancer].
    Huang C, Bei L, Liu T.
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1998 Aug 15; 20(4):285-8. PubMed ID: 11367693
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.